☆ 4.7 Article

Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Review Health Care Sciences & Services

Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches

Valeria Conti et al.

Summary: Long COVID or post-COVID-19 syndrome (PCS) refers to the development of persistent symptoms and/or complications in patients diagnosed with COVID-19. The pathogenesis and course of this syndrome are influenced by factors such as age, sex/gender, and pre-existing conditions. The lack of precise diagnostic and prognostic biomarkers complicates the clinical management of patients. This review aims to summarize recent evidence on the factors influencing PCS, possible biomarkers, and therapeutic approaches.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

News Item Medicine, General & Internal

What to Know About EG.5, the Latest SARS-CoV-2 Variant of Interest

Jennifer Abbasi

Summary: The article discusses EG.5, an Omicron descendant that may soon become the dominant variant globally.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Circulating Levels of PD-L1, TIM-3 and MMP-7 Are Promising Biomarkers to Differentiate COVID-19 Patients That Require Invasive Mechanical Ventilation

Leslie Chavez-Galan et al.

Summary: This study aimed to evaluate the disease severity of COVID-19 patients and identify potential biomarkers. The results showed that the levels of sPD-L1, sTIM-3, and sMMP-7 were associated with patients requiring invasive mechanical ventilation (IMV). Additionally, sMMP-7 could be a marker for the persistence of lung lesions post-COVID-19.

BIOMOLECULES (2022)

Add to Collection

Review Medicine, General & Internal

Identification of Drug Interaction Adverse Events in Patients With COVID-19 A Systematic Review

Valeria Conti et al.

Summary: This study systematically reviewed adverse clinical outcomes and adverse drug reactions caused by drug-drug interactions (DDIs) in patients with COVID-19. The findings showed that drug interaction checkers could identify various DDI-associated adverse drug reactions, including severe and life-threatening events. Therefore, it is important to evaluate the interactions between the drugs used to treat COVID-19 and between COVID-19 drugs and those already used by the patients.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Hematology

Immune checkpoint alterations and their blockade in COVID-19 patients

Jiaxiong Tan et al.

Summary: COVID-19 patients exhibit immune dysfunction characterized by abnormal expression of immune checkpoint proteins (ICs) on immune cells. Immunotherapy targeting ICs holds promise in improving immune function and clinical outcomes for COVID-19 patients. Further studies are needed to investigate the role of ICs and the impact of IC blockade in different populations or COVID-19 stages.

BLOOD SCIENCE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Role of cytokine storm in coronavirus infections: culprit or accomplice?

Rongpeng Xu et al.

Summary: There are currently seven known types of human coronaviruses (HCoVs), with low pathogenic and highly pathogenic categories. Low pathogenic HCoVs infect the upper respiratory tract, causing mild respiratory diseases. In contrast, highly pathogenic HCoVs infect the lower respiratory tract and cause fatal pneumonia, including diseases like SARS, MERS, and COVID-19. Understanding the role of cytokine storm in highly pathogenic HCoV infection is crucial.

FRONTIERS IN BIOSCIENCE-LANDMARK (2022)

Add to Collection

Letter Oncology

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

Rose K. C. Moritz et al.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Angelo Dipasquale et al.

Summary: The distinction between COVID-19 and immune-related pneumonia can be challenging in oncology practice, with a risk of lung injury by SARS-CoV-2 increasing the risk of immune-related adverse events. Screening before starting immunotherapy and awareness of this phenomenon can help interpret treatment changes and facilitate timely diagnostic work-up.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Multidisciplinary Sciences

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment

So Yeon Oh et al.

Summary: The study revealed that high levels of sPD-L1 in cancer patients were associated with progressive disease and worse prognosis, as well as positively correlated with neutrophil to lymphocyte ratios and negatively correlated with lymphocyte proportions and total numbers.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Infectious Diseases

Characteristics of viral pneumonia in the COVID-19 era: an update

P. Pagliano et al.

Summary: Viral pneumonia caused by influenza virus, rhinovirus, adenovirus, and coronavirus is a significant cause of community-acquired pneumonia, particularly in extreme age groups. Severe cases can result in respiratory failure, with the elderly and cancer patients being at higher risk of adverse outcomes.

INFECTION (2021)

Add to Collection

Article Medicine, Research & Experimental

PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response

Cristian Loretelli et al.

Summary: A significant proportion of COVID-19 recovered patients exhibit altered immune characteristics, with exhausted T cells and dysfunctional immune responses, including a poor reaction to viral antigens. Immune checkpoint blockade can ameliorate these post-COVID-19 immune abnormalities and enhance anti-SARS-CoV-2 immune responses.

JCI INSIGHT (2021)

Add to Collection

Review Immunology

Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis

Wenwei Qian et al.

Summary: The study found that cancer patients with prior exposure to ICIs had a higher hospitalization rate compared to those without, but the rates of severe disease and mortality were similar.

IMMUNOTHERAPY (2021)

Add to Collection

Article Geriatrics & Gerontology

BPIFB4 Circulating Levels and Its Prognostic Relevance in COVID-19

Elena Ciaglia et al.

Summary: Long-living individuals have higher levels of BPIFB4 and are more resistant to COVID-19, while COVID-19 patients show a significant decrease in BPIFB4 levels that correlates with disease severity. LAV-BPIFB4 has shown protective effects in the early stages of virus infection, suggesting new therapeutic possibilities for vulnerable populations.

JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2021)

Add to Collection

Review Microbiology

Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges

Al Hakim et al.

Summary: COVID-19, caused by SARS-CoV-2, shows high variability in clinical manifestations and post-disease complications, with age and comorbidities playing a significant role in disease severity.

FRONTIERS IN MICROBIOLOGY (2021)

Add to Collection

Review Pharmacology & Pharmacy

Immunotherapy Summary for Cytokine Storm in COVID-19

Yaqun Li et al.

Summary: COVID-19 pneumonia, caused by SARS-CoV-2, has disrupted the pro-inflammatory/anti-inflammatory response, leading to a need to neutralize cytokine storm. Current treatments focus on vaccines for prevention and immunomodulatory therapies to alleviate immune imbalance, with antiviral drugs and respiratory support as clinical options.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Immunology

PD-L1 Dysregulation in COVID-19 Patients

Francesco Sabbatino et al.

Summary: The COVID-19 pandemic has led to severe social and medical consequences, including a subset of patients with rapidly worsening severe-critical manifestations. Prognostic biomarkers and therapeutic approaches are urgently needed to address this issue. Dysregulated immune response, particularly involving immune checkpoint molecules like PD-1 and PD-L1, play a significant role in COVID-19 pathogenesis. Serum levels of PD-L1 have shown to have a prognostic role in COVID-19 patients, indicating the potential for PD-1/PD-L1 inhibitors in clinical studies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases

Christian Bailly et al.

Summary: This study highlights the biochemical and functional heterogeneity of soluble PD-L1 (sPD-L1) isoforms, generated by proteolysis or alternative splicing, and its role beyond cancer in various diseases and conditions such as inflammatory diseases and pregnancy.

CANCERS (2021)

Add to Collection

Article Immunology

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Chuan Qin et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Oncology

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Jia Luo et al.

CANCER DISCOVERY (2020)

Add to Collection

Article Medicine, General & Internal

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure

Jose Avendano-Ortiz et al.

MEDICINE (2020)

Add to Collection

Review Immunology

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Yujun Tang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Public, Environmental & Occupational Health

Immune response in COVID-19: A review

Mohammad Asaduzzaman Chowdhury et al.

JOURNAL OF INFECTION AND PUBLIC HEALTH (2020)

Add to Collection

Article Multidisciplinary Sciences

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Sara De Biasi et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Cell Biology

Soluble PD-L1 improved direct ARDS by reducing monocyte-derived macrophages

Jing Xu et al.

CELL DEATH & DISEASE (2020)

Add to Collection

Article Immunology

Immunological Biomarkers of COVID-19

Rongwei Lei et al.

CRITICAL REVIEWS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma

Xue Han et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study

Edward Gane et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Review Immunology

The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance

Guenther Schoenrich et al.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)

Add to Collection

Review Oncology

The clinical significance of soluble PD-1 and PD-L1 in lung cancer

Taher Abu Hejleh et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)

Add to Collection

Article Oncology

Cancer and the Immune System: The History and Background of Immunotherapy

Maura Abbott et al.

SEMINARS IN ONCOLOGY NURSING (2019)

Add to Collection

Article Medicine, General & Internal

Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C

Satoshi Yamagiwa et al.

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2017)

Add to Collection

Article Immunology

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

Cynthia L. Gay et al.

JOURNAL OF INFECTIOUS DISEASES (2017)

Add to Collection

Article Medicine, Research & Experimental

Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS)

Sean F. Monaghan et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2016)

Add to Collection

Article Immunology

PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells

Hyo Jin Park et al.

JOURNAL OF IMMUNOLOGY (2015)

Add to Collection

Article Geriatrics & Gerontology

Serum BPIFB4 levels classify health status in long-living individuals

Francesco Villa et al.

IMMUNITY & AGEING (2015)

Add to Collection

Article Immunology

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Loise M. Francisco et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2009)

Add to Collection

Article Multidisciplinary Sciences

Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes

J Wang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

Add to Collection

Article Immunology

The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice

MJI Ansari et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.